Kyndryl (KD) Q4 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Kindrel Fourth Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during this session, you will need to press 11 on your telephone. You would then hear an automated message advising your hand is raised. To withdraw your question, pl ...

EPR Properties (EPR) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 And welcome to the EPR Properties q one twenty twenty five earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I will now hand the call over to Brian Moriarty, Senior Vice President, ...

Liquidia Corp (LQDA) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, and welcome everyone to the Liquidia Corporation First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today. Currently, all participants are in a listen only mode. Following the presentation, we will conduct a question and answer session. Intra instructions will be provided at that time for you to queue up for questions. I would ...

Autolus Therapeutics (AUTL) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Autolus First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. Please ...

DENTSPLY SIRONA (XRAY) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Please be advised that today's conference is being recorded. I would now like to hand the call over to Andrea Daley, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, operator, and good morning, everyone. Welcome to the Dentsply Thirona first quarter twenty twenty five earnings call. Joining me for today's call is Simon Campion, Chief Executive Officer and Rich Rosenzweig, Executive Vice President, Corpor ...

Financial Data and Key Metrics Changes - The company reported record fee-related earnings (FRE) of $311 million, up 17% year over year [5][20] - FRE margin reached 48%, the highest level in several years [5][20] - Distributable earnings (DE) were $455 million, marking a record start to the year [18] - Assets under management (AUM) increased to $453 billion, up 6% year over year, driven by $50 billion of inflows over the past year [19][20] Business Line Data and Key Metrics Changes - Carlyle AlpInvest generated record FRE in the first quarter, nearly double from the same period last year, with AUM growing 12% to a record $89 billion [11] - Global Credit saw quarterly fee-related earnings surpassing $100 million for the first time, an increase of nearly 50% from last year [12] - Global Private Equity results were in line with expectations, with significant capital returned to investors, totaling nearly $8 billion over the past year [23] Market Data and Key Metrics Changes - The company noted strong momentum in private credit solutions, particularly in European lending, where deployment increased by 150% year over year [12] - The number of public companies in the U.S. has decreased nearly by half over the past two decades, while the number of private companies has increased more than fivefold, indicating a shift towards private market access [10] Company Strategy and Development Direction - The company is well-positioned to capitalize on new investment opportunities with $84 billion of dry powder available [8] - Carlyle is focusing on diversifying its business lines and leveraging its global brand to drive growth, particularly in wealth management and private equity [14][55] - The strategic initiative to grow capital markets is accelerating, with a record $150 million in fees generated over the past six months [13] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the macro environment, noting that while there are uncertainties, the long-term trends driving demand for private capital remain strong [9][19] - The impact of recent trade policies on investor sentiment and risk appetite was discussed, with management indicating that the majority of their portfolio is U.S.-based and less affected by tariffs [6][7] Other Important Information - The company has seen a doubling of evergreen inflows over the past year, indicating strong performance in its global wealth strategy [14] - Carlyle's diversified platform allows it to mobilize resources effectively during periods of market volatility [16] Q&A Session Summary Question: Impact of trade policy and tariffs on investment activity - Management noted that while there is a cautious approach among investors, there remains a willingness to deploy capital as long as policy implementation progresses positively [30][32] Question: Future of private equity franchise and fundraising - Management indicated no major adjustments to the timing of Fund IX, with a focus on performance and deployment in Fund VIII [36][91] Question: Insurance wins and fundraising guidance - The $40 billion flow guidance includes the recent insurance transactions, with strong performance in wealth products noted [45][96] Question: Endowment sector stress and its implications - Management does not foresee a significant decline in allocations to private capital from endowments, viewing potential opportunities for capital deployment [61][62] Question: Strategic alternatives in the insurance space - Management expressed a preference for organic growth but remains open to accretive acquisitions if they make sense [68][72] Question: Opportunities in Japan - The company highlighted a strong position in Japan, with expectations for continued growth in the market due to evolving corporate stewardship and asset management capabilities [76][78]

Mativ (MATV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Welcome to Mattev's First Quarter twenty twenty five Earnings Conference Call. On the call today from Mattev are Shruti Singhal, Chief Executive Officer Greg Weitzel, Chief Financial Officer and Chris Cooper, Director of Investor Relations. Today's call is being recorded and will be available for replay later this afternoon. At this time, all participants have been placed on a listen only mode and the floor will be open for your questions ...

Altice USA (ATUS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Greetings, and welcome to the Altice USA Q1 twenty twenty five As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Sarah Friedman, Vice President of Investor Relations. Speaker1 Thank you. Welcome to the Altice USA Q1 twenty twenty five earnings call. We are joined today by Altice USA's Chairman and CEO, Dennis Matthew and CFO, Mark Sarota, who together will take you through the presentation ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $9.2 million, down from $12.5 million in the prior year quarter, attributed to the timing of revenue recognition under the collaboration agreement with GSK [35] - Research and development expenses increased to $40.6 million from $33.4 million year-over-year, driven by spending on the Inhibin E program and RNA editing programs [35] - General and administrative expenses rose to $18.4 million from $13.5 million, primarily due to share-based compensation and professional fees [35] - Net loss for Q1 2025 was $46.9 million, compared to a net loss of $31.6 million in the prior year quarter [35] - Cash and cash equivalents at the end of Q1 2025 were $243.1 million, down from $302.1 million as of December 31, 2024, expected to fund operations into 2027 [35] Business Line Data and Key Metrics Changes - The company is advancing its clinical pipeline, including obesity, AATD, DMD, and HD programs, with significant progress reported in the last twelve months [6][7] - WVE-007 for obesity is designed to provide sustainable weight loss with infrequent dosing, showing promising preclinical data [8][10] - WVE-006 for AATD is positioned as a first treatment addressing the root cause of the disease, with ongoing clinical trials demonstrating durability of effect [12][13] - WVE-N531 for DMD has shown statistically significant improvements in muscle health and function, with plans for NDA submission in 2026 [15][20] Market Data and Key Metrics Changes - The obesity treatment market is evolving with the introduction of WVE-007, which aims to overcome limitations of current GLP-1 therapies [8][10] - The DMD market has a significant unmet need, with approximately 20,000 new cases annually, and current exon skipping therapies generating about $1.1 billion in sales in 2024 [19] - The Huntington's disease market is also underserved, with no disease-modifying therapies available, affecting over 200,000 people in the US and Europe [21] Company Strategy and Development Direction - The company is focused on unlocking the potential of RNA medicines, with a unique platform enabling a multimodal pipeline and pioneering RNA editing [6][7] - Plans include submitting NDAs for multiple candidates in 2026 and advancing a wholly owned discovery pipeline targeting both hepatic and extrahepatic diseases [14][30] - The company aims to differentiate its therapies through unique mechanisms of action and improved patient outcomes compared to existing treatments [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for significant data disclosures throughout 2025 [38] - The company is committed to engaging with regulatory agencies to ensure alignment on accelerated approval pathways for its therapies [45][86] - Management highlighted the importance of comprehensive data to support filings and the potential for transformative impacts on patient health [20][90] Other Important Information - The company is actively engaged in discussions with prospective strategic partners for its Huntington's disease program [23] - Upcoming data releases are expected to provide insights into the efficacy and safety of the company's pipeline candidates [28][34] Q&A Session Summary Question: What triggers data disclosure for the inhibit E program? - The company will look at time points such as one month, three months, and six months for data disclosure, with an internal cutoff for target engagement, weight loss, and biomarkers [41][43] Question: Are all drugs slated for accelerated approval under CDER? - Yes, the company confirmed that all drugs are under CDER, and discussions with the agency have remained consistent regarding the accelerated approval pathway [44][45] Question: What are the major pros and cons of RNA editing versus DNA editing? - RNA editing avoids bystander edits and potential irreversible collateral effects seen in DNA editing, making it a safer option for patients [58][61] Question: Why divide the dataset for AATD into two separate announcements? - The company believes that the 200 mg multidose data will be highly informative and does not plan to hold back data for the 400 mg cohort [71][72] Question: Will monthly dosing data be included in the NDA submission for DMD? - Yes, the plan is to include monthly dosing in the label, with ongoing discussions with the agency to support this [75][84]

Financial Data and Key Metrics Changes - For the fourth quarter of fiscal year 2025, revenue increased by 1% to approximately $205 million, while non-GAAP diluted earnings per share was $0.52, down approximately 5% year over year [7][24] - For the full fiscal year 2025, revenue was approximately $823 million, essentially flat year over year, down less than 1% [8][25] - Non-GAAP EPS for the full fiscal year 2025 was $2.22, a 1% improvement over fiscal year 2024 [8][26] Business Line Data and Key Metrics Changes - Service assurance revenue declined approximately 4% year over year, partially due to the divestiture of the test optimization business [9][27] - Cybersecurity offerings delivered nearly 7% year over year revenue growth, driven by strong momentum within the enterprise customer vertical [11][27] Market Data and Key Metrics Changes - The enterprise customer vertical grew by 7.5%, while the service provider customer vertical revenue decreased by 10.1% [27] - 57% of total revenue came from the enterprise customer vertical, while 43% came from the service provider vertical [27][28] Company Strategy and Development Direction - The company plans to continue investing in innovation and deepen relationships with customers while leveraging mission-critical solutions to support evolving performance, availability, and security needs [14][13] - The long-term strategy remains unchanged, focusing on sustainable long-term success [14] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding growth in the cybersecurity offerings despite broader economic uncertainty [13][12] - The company expects fiscal year 2026 revenue to be in the range of approximately $825 million to $865 million, with non-GAAP diluted EPS expected between $2.25 and $2.40 [32] Other Important Information - A leadership transition was announced, with the current CEO and CFO retiring effective May 31, 2025, and successors appointed [16][17] - The company ended fiscal year 2025 with $492.5 million in cash and cash equivalents, representing an increase of $68.4 million since the end of fiscal year 2024 [28][29] Q&A Session Summary Question: Impact of tariffs on customer sentiment and guidance - Management noted some delayed sales cycles but indicated that guidance covers uncertainties, with a wait-and-see approach from customers regarding order timing [38][40] Question: Cybersecurity momentum and new product expectations - Management highlighted that the service assurance business is evolving into a broader observability market, which presents opportunities for growth in both service assurance and cybersecurity [41][43] Question: Interest in software-only solutions - Management confirmed a consistent demand for software solutions, with a focus on maintaining high margins despite growth challenges [50] Question: Contribution from government and defense business - Management indicated no significant impact from recent headlines on sales cycles, but noted that the pipeline remains a question mark for future contributions [52]